Steve Nicholls Articles

LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque in ACS patients

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Stephen Nicholls 

Should ACS patients start a PCSK9 inhibitor in hospital?

Guidelines recommend that very high-risk patients require combination lipid lowering therapy, ideally the combination of statin-ezetimibe and a PCSK9 inhibitor, to attain LDL cholesterol goal. The question is whether those with an acute coronary syndrome (ACS) should initiate a PCSK9 inhibitor with intensive statin therapy…

APOLLO trial with SLN360

Professor Stephen Nicholls (Monash University, Australia) discusses the APOLLO trial with SLN360.  

Huygens: Does PCSK9 inhibition impact the vulnerable plaque?

The HUYGENS study (High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study NCT03570697) investigated the impact of PCSK9 inhibition on the vulnerable plaque. Results were reported at ESC Congress 2021 (Virtual). Professor Stephen Nicholls, Monash University, Melbourne, Australia discusses the background to the…

Triglyceride lowering and residual risk: what can we learn from the trials?

VIDEO: Prof Steve Nicholls discusses STRENGTH

News from AHA 2020 Virtual: Professor Steve Nicholls (Monash University, Melbourne, Australia) puts the STRENGTH results in context

VIDEO: Prof Steve Nicholls fish oils and AF

News from AHA 2020 Virtual: Professor Steve Nicholls (Monash University, Melbourne, Australia) discusses fish oils and risk for atrial fibrillation and implications for clinical practice

VIDEO: Prof Stephen Nicholls Targeting PCSK9 inhibitors to the right patient

Targeting PCSK9 inhibitors to the right patient

Professor Stephen J Nicholls MBBS PhD, Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia  The clinical development of pharmacological inhibitors of proprotein convertase subtilisin kexin type 9 (PCSK9) has received considerable attention by virtue of the expectation that these treatments would have the potential to…

VIDEO: Prof Stephen Nicholls Effect of alirocumab on MI types

Will FOURIER and ODYSSEY Outcomes change LDL cholesterol goals in high-risk patients?

Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): How do you interpret the mortality data from ODYSSEY Outcomes?

Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): Would you have expected a greater magnitude of benefit for the primary outcome in ODYSSEY Outcomes?

Does ODYSSEY Outcomes align with FOURIER and the SPIRE cardiovascular outcomes studies?

Prof Steve Nicholls: How can FOURIER improve our clinical practice?

Prof Steve Nicholls: Is there a link between the benefit of evolocumab observed in GLAGOV & FOURIER?

Prof Steve Nicholls: Is FOURIER a game changer?

Current status of IVUS studies of plaque burden: what next with GLAGOV?

Over the last decade, the use of serial intravascular ultrasound (IVUS) imaging has been critical for defining the relationship between achieved LDL cholesterol levels and atherosclerotic plaque burden. In this overview, Professor Steve Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia) discusses the…

Innovative PCSK9-targeted therapeutics: siRNA

Stephen Nicholls

ESC Congress 2015 buzz: Novel LDL lowering treatments

Professor Steve Nicholls, University of Adelaide, Adelaide, Australia discusses the PCSK9 inhibitors versus CETP inhibitors